La Jolla Pharmaceutical Company intended to significantly improve outcomes in patients suffering from life-threatening diseases. nda planned for new investigational product, ljpc-0118, for the treatment of severe malaria, in fourth quarter of 2019: la jolla plans to file a new drug application (nda) with the u.s. food and drug administration in the fourth quarter of 2019 for ljpc-0118. ljpc-0118 is la jolla’s new investigational product for the treatment of severe malaria. the active pharmaceutical ingredient in ljpc-0118 was demonstrated to be superior to quinine in reducing mortality in patients with severe falciparum malaria infection in two randomized, controlled, clinical studies. topline results of phase 2 study of ljpc-401 in patients with hereditary hemochromatosis expected in second half of 2019: la jolla expects topline results in the second half of 2019 for lj401-hh01, a multinational, multicenter, randomized, phase 2 study that is designed to evaluate the safety and efficacy of ljpc-401, la jolla’s proprietary formulation of synthetic human hepcidin, as a treatment for hereditary hemochromatosis. the primary efficacy endpoint of the study is the change in transferrin saturation, a standard measurement of iron levels in the body and one of the two key measurements used to detect iron overload, from baseline to end of treatment. Topline Results of Pivotal Study of LJPC-401 in Patients with Beta Thalassemia Expected in Mid-2020: La Jolla expects topline results in mid-2020 for LJ401-BT01, a pivotal, multinational, multicenter, randomized, controlled study that is designed to evaluate the safety and efficacy of LJPC-401 as a treatment for beta thalassemia patients who, despite chelation therapy, have cardiac iron levels above normal. The primary efficacy endpoint of this study is the change in iron content in the heart after 6 months, as measured by cardiac magnetic resonance imaging. If this study is successful, La Jolla anticipates filing an MAA for LJPC-401 in the European Union.